Lenalidomide-Associated Hemophagocytic Lymphohistiocytosis With Plasma Cell Phagocytosis

Elliot Runge, Chung-Ting J Kou, Matthew Rendo, David Lynch, Joshua Fenderson

Research output: Contribution to journalArticlepeer-review


Hemophagocytic lymphohistiocytosis (HLH) is a severe systemic inflammatory syndrome that is often fatal. In the adult population, it is believed to develop secondary to immune dysregulation due to rheumatologic, infectious, malignant, and recently, immunomodulatory drugs. It's co-occurrence with phagocytosis by non-macrophage cells has not been previously well defined. We present a case of lenalidomide-associated HLH with concurrent plasma cell hemophagocytosis in a patient with controlled multiple myeloma (MM).

Original languageEnglish
Pages (from-to)e14409
Issue number4
StatePublished - 10 Apr 2021


Dive into the research topics of 'Lenalidomide-Associated Hemophagocytic Lymphohistiocytosis With Plasma Cell Phagocytosis'. Together they form a unique fingerprint.

Cite this